Rapid roll out of SARS-CoV-2 antibody testing-a concern
- PMID: 32580928
- DOI: 10.1136/bmj.m2420
Rapid roll out of SARS-CoV-2 antibody testing-a concern
Conflict of interest statement
Competing interests: IB: chief data scientist adviser for AstraZeneca through the University of Liverpool. WI: speaker and consultancy fees from Roche, Janssen Cilag, Gilead Sciences, and Novartis; educational grants from Boehringer Ingelheim, Merck Sharp and Dohme, and Gilead Sciences; and research grant support from GlaxoSmithKline, Pfizer, Gilead Sciences, Janssen Cilag, Abbvie, and Bristol-Myers Squibb. All other authors: none declared.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
